Covid-19 Vaccine: ZyCoV-D

Covid-19 Vaccine: ZyCoV-D

GS-PAPER-3 S&T

Recently, India has started phase I/II clinical trials of Covid-19 vaccine - ZyCoV-D, designed and developed by Zydus (a pharmaceutical company) with support from the Department of Biotechnology (DBT).

The adaptive phase I/II clinical trials will assess the safety, tolerability and immunogenicity of the vaccine. The other indigenously developed vaccine - Covaxin - produced by Hyderabad based Bharat Biotech is also underway to start clinical trials.

Imp Points

Description: ZyCoV-D, a plasmid DNA vaccine, comes under the Vaccine Discovery Programme supported by the Department of Biotechnology under the National Biopharma Mission.

National Biopharma Mission

It is an industry-academia collaborative mission for accelerating biopharmaceutical development in the country.
It was launched in 2017 at a total cost of Rs. 1500 crore and is 50% co-funded by World Bank loan.
It is being implemented by the Biotechnology Industry Research Assistance Council (BIRAC).

(BIRAC is a Public Sector Enterprise, set up by the Department of Biotechnology (DBT), Ministry of Science & Technology)

Under this Mission, the Government has launched Innovate in India (i3) programme to create an enabling ecosystem to promote entrepreneurship and indigenous manufacturing in the biopharma sector.
Objectives: Development of vaccines, medical devices, diagnostics and biotherapeutics besides, strengthening the clinical trial capacity and building technology transfer capabilities in the country.

Plasmids are circular deoxyribonucleic acid (DNA) vectors that can be used as vaccines to prevent various types of diseases.

Pre-Clinical Phase: It was found to initiate a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits.
- The antibodies produced by the vaccine were able to neutralize the wild type virus indicating the protective potential of the vaccine candidate.
- No safety concerns were observed in repeat dose by both intramuscular (directly into muscles)
- intradermal (superficial injection into skin) routes of administration.
DNA Vaccine Platform: The development of ZyCov-D has established the DNA vaccine platform in the country which is simple to deploy, temperature stable, and consistently manufacturable- thus lowering costs and enhancing the effectiveness of a vaccine.

It provides ease of manufacturing the vaccine with minimal biosafety requirements. It has shown much improved vaccine stability and lower cold chain requirements making it easy for transportation to remote regions of the country. Furthermore, the platform can be rapidly used to modify the vaccine in a couple of weeks in case the virus mutates.

Source: IE

Join Our Telegram

COVID19- Mom to child transmission

Delimitation: North-east Illegal

India’s Indo-Pacific Oceans Initiative (IPOI) UPSC GS-2 INDO PACIFIC – IR/PSIR

20 Nov, 25
SHARE

India’s Indo-Pacific Oceans Initiative (IPOI) UPSC GS-2 INDO PACIFIC – IR/PSIR IPOI is India’s open, voluntary and non-treaty-based maritime initiative for building a free, open, inclusive and rules-based Indo-Pacific through practical cooperation. Why in News? India’s Indo-Pacific Oceans Ini

AI Impact Summit 2026 UPSC GS-3 S&T PT-MAINS

19 May, 26
SHARE

AI Impact Summit 2026 UPSC GS-3 S&T PT-MAINS The India-AI Impact Summit 2026 positioned India as a Global South leader by shifting global AI debate from only AI safety and regulation to AI for development, inclusion and real-world impact. Why in News? India hosted the India-AI Impact Summit 2026 at B

Hong Kong Convention for Safe Ship Recycling UPSC GS-3 ENVIRONMENT PT-MAINS

27 Jun, 25
SHARE

Hong Kong Convention for Safe Ship Recycling UPSC GS-3 ENVIRONMENT PT-MAINS The Hong Kong International Convention, 2009 is an IMO treaty that ensures ships are recycled safely without unnecessary risk to human health, worker safety and the environment. Why in News? The Hong Kong Convention entered into force on 26 June 2

LeadIT 2.0: Leadership Group for Industry Transition COP28 UPSC GS-2 IR GS-3 S&T

14 Nov, 23
SHARE

LeadIT 2.0: Leadership Group for Industry Transition UPSC GS-2 IR GS-3 S&T LeadIT 2.0 is the second phase of the India-Sweden-led global initiative to support low-carbon transition in hard-to-abate industrial sectors. Why in News? The second phase of LeadIT was announced at the LeadIT Summit 2023, ho

India-EFTA Trade and Economic Partnership Agreement UPSC GS-2 IR/PSIR

03 Sep, 25
SHARE

India-EFTA Trade and Economic Partnership Agreement UPSC GS-2 IR/PSIR The India-EFTA TEPA is a comprehensive trade pact between India and four non-EU European countries — Iceland, Liechtenstein, Norway and Switzerland — aimed at boosting trade, investment, jobs, services, technology and supply-chain resilience. Wh